Learning Objectives:
1. Recognize bullous epithelial keratopathy as a rare complication of netarsudil
2. Understand that Descemet stripping endothelial keratoplasty is a viable therapeutic option if the keratopathy does not resolve with cessation of netarsudil
3. Describe the key factors that contribute to prognosis of ocular melanoma
4. Describe treatment modalities available for ocular melanoma and the treatment trials
5. Describe the systemic workup for metastatic uveal melanoma
Session date:
08/13/2021 - 7:30am to 9:00am CDT
Location:
Glenbrook Hospital, Conference Rooms A1-A2
United States
See map: Google Maps
Add to calendar:
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Speaker Name:
Jacob Kanter, MD and Ian Patterson, MD